These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28383390)

  • 1. High Prevalence of Abacavir-associated L74V/I Mutations in Kenyan Children Failing Antiretroviral Therapy.
    Dziuban EJ; DeVos J; Ngeno B; Ngugi E; Zhang G; Sabatier J; Wagar N; Diallo K; Nganga L; Katana A; Yang C; Rivadeneira ED; Mukui I; Odhiambo F; Redfield R; Raizes E
    Pediatr Infect Dis J; 2017 Aug; 36(8):758-760. PubMed ID: 28383390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
    Ferrer E; Niubo J; Crespo M; Gatell JM; Sanz J; Veloso S; Llibre JM; Barrufet P; Sanchez P; Podzamczer D;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):253-5. PubMed ID: 17895768
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
    Lanier ER; Givens N; Stone C; Griffin P; Gibb D; Walker S; Tisdale M; Irlbeck D; Underwood M; St Clair M; Ait-Khaled M
    HIV Med; 2004 Nov; 5(6):394-9. PubMed ID: 15544690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
    Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
    Troya J; Ryan P; Montejano R; Cabello A; Cuevas G; Matarranz M; Cañamares I; Solís J; Walther LÁ
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):423-426. PubMed ID: 30443683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient monitoring of HIV-1 vertically infected children in Kenya on first-line antiretroviral therapy.
    Lihana RW; Lwembe RM; Bi X; Ochieng W; Panikulam A; Palakudy T; Musoke R; Owens M; Ishizaki A; Okoth FA; Songok EM; Ichimura H
    J Clin Virol; 2011 Oct; 52(2):123-8. PubMed ID: 21798798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
    Steegen K; Levin L; Ketseoglou I; Bronze M; Papathanasopoulos MA; Carmona S; Stevens W
    PLoS One; 2014; 9(5):e97067. PubMed ID: 24816790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
    Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
    AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance and cross-resistance to abacavir.
    Moyle G
    HIV Med; 2001 Jul; 2(3):154-62. PubMed ID: 11737395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral drug resistance among HIV-1 infected children failing treatment.
    Mullen J; Leech S; O'Shea S; Chrystie IL; Du Mont G; Ball C; Sharland M; Cottam F; Zuckerman M; Rice P; Easterbrook P
    J Med Virol; 2002 Nov; 68(3):299-304. PubMed ID: 12226814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
    Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
    J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
    Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy.
    Crawford KW; Njeru D; Maswai J; Omondi M; Apollo D; Kimetto J; Gitonga L; Munyao J; Langat R; Aoko A; Tarus J; Khamadi S; Hamm TE
    AIDS; 2014 Jan; 28(3):442-5. PubMed ID: 24670527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
    Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG
    Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.